VPC-18005

• Description:

  VPC-18005 inhibits ERG-induced transcription and interacts directly with the ERG-ETS domain, and disrupts the ERG binding to DNA. VPC-18005 is a potent inhibitor of luciferase activity[1].

• UNSPSC:

  12352005

• Target:

  DNA/RNA Synthesis

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/vpc-18005.html

• Purity:

  99.80

• Solubility:

  DMSO : 62.5 mg/mL (ultrasonic)

• Smiles:

  O=C(O)CC(S/C(N1)=N\N=C/C2=CC=C(C(C)C)C=C2)C1=O

• Molecular Formula:

  C15H17N3O3S

• Molecular Weight:

  319.38

• References & Citations:

  [1]Miriam S Butler, et al. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Oncotarget. 2017 Jun 27;8 (26) :42438-42454.|[2]Haneen Amawi, et al. The use of zebrafish model in prostate cancer therapeutic development and discovery. Cancer Chemother Pharmacol. 2021 Mar;87 (3) :311-325.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• CAS Number:

  [2242480-48-2]